Innovative Cost Reduction Neofluidics offers a disruptive NeoPlate™ system that significantly lowers primary drug screening costs by nearly 99%, presenting a compelling value proposition for pharmaceutical companies seeking cost-efficient high throughput screening solutions.

Adaptable Technology The company's lab-on-a-chip technology is compatible with most existing robotic liquid handling systems, enabling seamless integration and easy adoption across laboratories, which can be a key selling point when targeting research and biotech firms.

Expanding Applications Neofluidics has diversified its product offerings into areas like single-cell analysis and tissue organ modeling, opening avenues for sales within cancer research, immunology, genetic studies, and drug toxicity testing markets.

Emerging Market Presence Although the company is small with a revenue under $1 million, its established product lines and positive client outreach across North America and abroad suggest growth potential in niche markets such as petroleum and military segments.

Technology Portfolio Holding proprietary patents in lab-on-a-chip technology and delivering multiple product lines, Neofluidics offers unique and defensible solutions that can be positioned as cutting-edge tools for organizations aiming to advance research capabilities.